Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of L03RD1/L03RD2 vs L03TD1 in Healthy Volunteers
NCT07533539Phase 1Completed
- Sponsor
- Celltrion
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of interferon beta-1a in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Celltrion. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable concentration and Maximum observed plasma concentration. Started May 2026; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07533539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533539.